IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium
- Professor Fukuma's positive testimonial on ProSense's effectiveness and minimal side effects
- Partnership with Terumo Thailand expected to improve sales momentum
- None.
- Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense
- IceCure joined its exclusive regional distributor, Terumo, to exhibit the ProSense System to physicians seeking minimally invasive alternatives to lumpectomy
A cryoablation symposium, "Cryoablation Emerging as Effective Treatment for Breast Cancer", was led by Professor Eisuke Fukuma, Director of the Breast Center at Kameda Medical Center,
Professor Fukuma commented, "I've performed over 600 breast tumor procedures with ProSense with excellent results. Patients have minimal pain, no change to the volume or the shape of the breast, and they can quickly resume their normal activities the day following the procedure. Because of this, many women come to my facility and seek out cryoablation. I am pleased to be here at the conference to inform and educate other doctors on how to use ProSense to benefit their patients."
"The growing amount of data on ProSense's efficacy in treating tumors of the breast, lung, and kidney supports our sales momentum in
IceCure's Tlalit Bussi Tel-Tzure, commented, "We had very strong interest in ProSense both at the Terumo booth and at Professor Fukuma's talk. The awareness around cryoablation as a minimally invasive method to treat early-stage breast cancer continues to gain momentum and ProSense is extremely well positioned as the system of choice for breast surgeons. Terumo has been a great partner for us in
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward looking Statements
This press release contains forward looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other federal and Israeli securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward looking statements. For example, IceCure is using forward looking statement in this press release when it discusses that IceCure's breakthrough technology marks a new era in women's health treatment, that this technology represents a new hope for patients who face a cancer diagnosis, that the partnership between IceCure and Terumo Thailand will improve the lives of Thais and Israelis, that the ProSense System is well positioned as the system of choice for breast surgeons and that IceCure expects to see growing sales momentum in
IR Contact:
Michael Polyviou
Phone: 732-232-6914
Email: mpolyviou@evcgroup.com
Todd Kerhli
Phone: 310-625-4462
Email: tkehrli@evcgroup.com
Logo - https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecure-medical-continues-to-experience-growing-global-interest-in-prosense-featured-at-the-16th-thai-breast-symposium-301905403.html
SOURCE IceCure Medical